Bluefish wins tender auction in Spain

Two-year contract for oncolocy products in Andalusia region

Bluefish has been selected as the exclusive provider of four products within the oncology area in a two-year contract for the Andalusia region. The products are Anastrozole 1mg, Bicalutamide 50mg, Bicalutamide 150mg and Letrozole 2.5mg. Initial supply is planned for early 2014. Additional net sales from the contract is estimated to approximately SEK 15 million per year.

While tender auctions for pharmaceuticals are common practice throughout Europe, so far, Andalusia is the only one of Spain’s 17 different regions where this method is applied.

Bluefish has successfully built market share in major European markets by offering high quality generic pharmaceuticals. Never compromising on product quality and patient safety, we market our products in an innovative, responsible and cost-efficient way with the ambition of making modern medicines accessible to more people.

Bluefish is operating in a large number of European markets. Our product portfolio consists of 80 products and is growing.

For more information, contact

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: susanna.urdmark@bluefishpharma.com

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of 80 products and is growing.

www.bluefishpharma.com